Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study - Wikidata - wikimedia - TriplyDB

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

http://www.wikidata.org/entity/Q28196342

about

Inherited thrombophilia and reproductive disorders Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review Guidance for the evaluation and treatment of hereditary and acquired thrombophilia Patients' understanding of genetic susceptibility testing in mainstream medicine: qualitative study on thrombophilia An Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective.The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies.Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer Ethical issues raised by common copy number variants and single nucleotide polymorphisms of certain and uncertain significance in general medical practice Family history of venous thromboembolism and identifying factor V Leiden carriers during pregnancy Prevalence of thromogenic gene mutations in women with recurrent miscarriage: A retrospective study of 1,507 patients.Evidence-based approach to thrombophilia testing.Does thrombophilia testing help in the clinical management of patients?The case for randomized controlled trials to assess the impact of clinical information systems Use of Factor V Leiden genetic testing in practice and impact on management Importance of risk factors for the evaluation of patients with a suspected pulmonary embolism.Lower extremity venous thrombosis in patients younger than 50 years of age Analysis of Thrombophilia Test Ordering Practices at an Academic Center: A Proposal for Appropriate Testing to Reduce Harm and Cost.Factor V-Leiden Mutation: A Common Risk Factor for Venous Thrombosis among Lebanese Patients.Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia.Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions.Genetic variations and their influence on risk and treatment of venous thrombosis.Secondary effects of antipsychotics: women at greater risk than men.Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study.Contraception in women with medical problems.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome.Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?Testing for thrombophilia: pitfalls, limitations, and marginal impact on treatment duration recommendations.Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.Review of Management and Outcomes in Women with Thrombophilia Risk during Pregnancy at a Single Institution.Coagulation disorders in pregnancy: acquired and inherited thrombophilias.Cost effectiveness of pharmacogenomics: a critical and systematic review.ABO blood groups and thrombosis: a causal association, but is there value in screening?Low molecular weight heparin in obstetric care: a review of the literature.Ovarian hyperstimulation syndrome and thrombotic events.The Role of Anticoagulants in the Prevention of Pregnancy Complications.'To test or not to test', the arguments for and against thrombophilia testing in obstetrics.Discontinuation of modern hormonal contraceptives: an Italian survey.

P2860

Q26749462-092B68F8-A96F-4EB1-A352-66CC261B4005 Q26859762-C24D95B0-8CE9-4413-93BA-F56DBF52DEFB Q28077943-25D8FC0F-1F8E-4F7D-84E3-1DCE1834A33A Q28213173-C5E068DE-0019-4E5F-9ED7-59CF0493360F Q30409124-70AB5BA1-9738-474F-B91E-8672190F5740 Q33610047-614E94CA-E5FC-422C-8CA4-469534CEB2EB Q33726931-FB6028C0-BA48-4CCB-9B70-C228266898AB Q33965106-66635305-75AB-4938-9410-A38618996550 Q34073493-C5911159-0763-4498-BAFB-610AC17BC21C Q34416717-0F5799DF-9AFC-4007-AE57-FF6701C18F3C Q34577045-B1FA9872-E495-490E-B34B-A3C5A1E71155 Q34663749-43E3C5BE-8E43-4F6F-BAF0-A3C83CA13FDD Q34810086-F842671A-3CB1-4BA3-AE43-8D66D7AF5F8D Q35048795-2690ADDA-4C51-43FC-A284-217FE52CDB4C Q35093438-BAB21BBD-3879-4370-9043-8D4E6EA6ADCA Q35758047-1AF958E0-35D4-43B7-8057-E5AA8CA559D8 Q35846703-725A3362-CC35-4A66-92ED-3FBF53011570 Q36017106-5119234B-E9DA-44A7-9855-94CF956016B0 Q36045799-A14442DD-B708-4F73-B09A-4733C98226C8 Q36201247-D0FCE50C-F9DA-4B47-B92D-DA31C5EF45D7 Q36662483-33BBB752-A59F-46AC-A8E4-28CE4290FDBC Q36858688-1BE3A221-0355-4E46-8EAC-13826C593C7D Q37126654-2D3FCD65-83D0-4EAD-86F5-97E484435CC4 Q37133664-00DF24B5-5412-4A3C-828A-6BE4E6A78455 Q37171730-3E2CF050-17B9-451D-B688-3D93CC9DA7A9 Q37186251-91695495-E355-4F87-AE0D-997800592780 Q37251490-C1BAF2C5-C463-467D-878C-C97970897DC8 Q37270797-DAB39F11-81F1-4BA7-A72E-3670D36BA587 Q37302477-DBFA9CFF-6279-46A7-B75C-8B320BB2CB16 Q37473272-FA9D4F0D-D029-43B3-AFDD-B42CD114A98E Q37479967-E579B1A6-AAE7-4E3E-8BA6-66D513EF6D79 Q37622772-0E97F8E7-0266-480F-AFD7-4D732DED743A Q37788749-A3341118-D864-48C4-A52E-7439286908C8 Q37799352-C07D98BB-042C-46B3-B37D-9ED2CC293814 Q37859751-02D06C75-997C-48DB-8798-80337FF7875C Q37892215-02AC736F-5336-4EA4-955A-8D068ED849D9 Q38242118-8D5927CF-CBCB-48D2-BF69-2D0791F2FC30 Q38632931-8C629602-DBCC-49AE-935E-A0ED16BC88B9 Q38692085-D9632478-72F3-42E0-83F5-9F3FA0C29192 Q38974888-A0F1177D-7C86-41C1-876F-C562D0EB240C

P2860

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

http://www.wikidata.org/entity/Q28196342

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@ast

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@en

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@nl

type

label

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@ast

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@en

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@nl

prefLabel

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@ast

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@en

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@nl

P1433

Q28196342-D3E30DBB-3748-470E-9A68-56D841E26A5E

P1476

Q28196342-F9590469-0631-4C40-8323-7FD90EEF8D87

P2093

Q28196342-08AC85F4-94C7-40DB-9A2A-D9F31A956691

Q28196342-4BF447D5-3ED9-4BED-B3F3-B308EC1EEB40

Q28196342-54F77BFD-F602-446F-BCA4-74B372D9FD96

Q28196342-5DEBA02A-94DC-49FF-B457-969D0D42C0E8

Q28196342-6913B5D4-152A-4E63-95A4-60117ED81F85

Q28196342-755FB5EF-3B6C-4EB7-94F5-CE43FF5481B8

Q28196342-9FC8B3E7-C5E3-40AC-B525-4ABA031C53C3

Q28196342-AC45616C-FD5E-457A-8D6E-A3287C9BF16F

Q28196342-B2BE7D9C-CD4E-4AC9-92F7-6DFC52E2C02E

Q28196342-C61E3D44-0C6D-41CC-B20F-974A4AB0611C

P304

Q28196342-2063CB24-EFEF-4596-876E-7CF07F023338

P31

Q28196342-6ABB1A97-9DD4-45DA-AB2E-1A820F6BBF15

Q28196342-D80E4795-A516-4485-BAA2-936B4DC10159

P3181

Q28196342-18D27314-B8CA-419A-B387-EFE9DB84A8FF

P356

Q28196342-4634DFB9-F1DE-4F99-8A4C-EC8F8D8100DC

P407

Q28196342-685EA52F-1830-4935-B3AE-D01F2ECB3B45

P433

Q28196342-7F6A367A-F216-43E8-8AC8-A527E3851BF9

P478

Q28196342-036D6A3D-F1AB-4C23-A9E4-92FBDBFAA699

P577

Q28196342-205E0250-813C-4A1D-8A83-6538D6FD290A

P5875

Q28196342-D1D02904-B62A-4F9C-8BC8-C1D83F8BEF89

P698

Q28196342-F0486A77-A605-40A7-92F9-76AF2FC894A9

P921

Q28196342-4CC0DACA-59F3-4914-AC23-A994B76D9619

Q28196342-E9EAD129-7FAA-4A82-93CE-EF6E5E19D43C

P3181

P356

P1433

Health Technology Assessment

P1476

Screening for thrombophilia in ...... hilia Screening (TREATS) study

@en

P2093

G D O Lowe

http://www.w3.org/2001/XMLSchema#string

I Brenkel

http://www.w3.org/2001/XMLSchema#string

I D Walker

http://www.w3.org/2001/XMLSchema#string

I Greer

http://www.w3.org/2001/XMLSchema#string

L Regan

http://www.w3.org/2001/XMLSchema#string

L Robertson

http://www.w3.org/2001/XMLSchema#string

M Greaves

http://www.w3.org/2001/XMLSchema#string

O Wu

http://www.w3.org/2001/XMLSchema#string

P Clark

http://www.w3.org/2001/XMLSchema#string

P Langhorne

http://www.w3.org/2001/XMLSchema#string

P304

1-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

1662998

http://www.w3.org/2001/XMLSchema#string

P356

10.3310/HTA10110

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7184874

http://www.w3.org/2001/XMLSchema#string

P698

16595080

http://www.w3.org/2001/XMLSchema#string

P921